drug development Related News
Fibrinolytic therapy: discover the blood thinning medication
According to research presented at the American College of Cardiology’s 68th Annual Scientific Session, a new blood thinning medication could be effective in fibrinolytic...
CBD products: the goods in legal limbo and in high demand
Cura Partners, Inc. is a US-based company expanding into international markets with its brand of CBD products Select CBD, and this is part of...
An introduction to Columbia Care: a world-class medical cannabis business
Its unparalleled cannabis-based products and ongoing commitment to rigorous scientific research make Columbia Care LLC a world leader in medical cannabis.
CEO Nicholas Vita talks...
Let’s talk medical cannabis with Sigma Analytical Services
As legalisation of medical cannabis and cannabis-derived products expands globally, Sigma Analytical Services is establishing itself as a pioneer.
Understanding the complex chemistry of cannabis...
Systemic corticosteroids: can severe asthma patients benefit from this?
Physicians may have discovered a way to predict which patients with severe asthma are likely to benefit from treatment with systemic corticosteroids.
With the help...
Could there be a new treatment for ovarian cancer?
According to scientists from the University of Sheffield, UK, a drug compound could be a new treatment for ovarian cancer.
Typically, chemotherapy is still the...
Did you know drug combination could treat advanced kidney cancer?
According to researchers from Dana-Farber Cancer Institute, USA, a drug combination could potentially become the first-line treatment for patients with advanced kidney cancer.
Patients who...
Cannabis-based medicine to be tested in Azheimer’s trial
Alzheimer’s Research UK is committing nearly £300,000 (~€341,000) for a landmark phase II clinical trial of Sativex®, a cannabis-based medicine licensed in the UK.
The...
The New Modalities Ecosystem: a much-needed boost for rare diseases
The collaborative New Modalities Ecosystem unites academia, pharma and technology companies to drive real and meaningful progress in research and treatments for rare diseases.
IN...
Patient groups: our strongest weapon against rare diseases
Findacure CEO Rick Thompson sets out the crucial role of patient groups in developing new treatments for rare diseases.
Rare diseases are defined in Europe...
How to deal with the medical cannabis dilemma
Dr Franjo Grotenhermen, the executive director of the International Association for Cannabinoid Medicines, reflects on the legal challenges around medical cannabis.
There is a general...
TILRAY: the medical cannabis research global leader
Medical cannabis is rapidly gaining momentum across the globe, and Tilray Inc. is pioneering the production, research, and distribution of medical cannabis.
This ebook explores...
Rare blood disorders: could sutimlimab treat the untreatable?
Researchers yearn to treat rare blood disorders, and now they may have found the solution with the investigational drug, sutimlimab.
Sutimlimab has shown promising results...
Could llama blood be the unlikely ally in producing antibody therapeutics?
Researchers have used llamas to produce new antibody therapeutics with the potential to work against all types of flu, including new pandemics.
After testing 60...
The growth of medical cannabis in Europe
Stephen Murphy, the co-founder and managing director of Prohibition Partners, shares his thoughts on the evolving landscape of medical cannabis in Europe and looks...
EU-OPENSCREEN: research infrastructure and medicinal chemistry
Dr Wolfgang Fecke introduces EU-OPENSCREEN, a European Research Infrastructure Consortium for medicinal chemistry, supporting research and its translation to medicine and agriculture.
The systematic screening...
Michael Lisanti and antibiotics: the next cancer revolution
Speaking to Health Europa, Professor Michael Lisanti, MD-PhD, FRSA discusses the potential role of antibiotics in preventing the recurrence of cancer.
How would you cure...
From highly priced medicines to Medicines That Matter
Highly priced medicines represent a significant public health challenge. Global health advocate Ella Weggen shares how Wemos is responding through its dedicated project Medicines...
BioBlocks, Inc.: Transforming the process of lead discovery
BioBlocks CEO Dr Peter Pallai discusses how BioBlocks is making drug discovery more straightforward, faster and more economical using data-driven approaches.
BioBlocks is a medicinal...
Open Targets – transforming drug discovery
Health Europa talks with Open Targets who discuss how the platform works to systematically identify and prioritise drug discovery to develop safe and effective...